Clinically, INHBA agonists can promote the INHBA-ACVR1B pathway to eliminate SF1 lineage pituitary tumors or increase the infiltration of CX3CR1+ macrophages in other lineages, helping PitNET treatment. Here, SF1 is linked to pituitary tumor.